The top 100 list of the national pharmaceutical industry came out, and two pharmaceutical companies made it into the top 10

On August 30, the 2020 (37th) National Pharmaceutical Industry Information Conference and the 2019 China Pharmaceutical Industry Top 100 List, hosted by the China Pharmaceutical Industry Information Center, were held in Zhuhai.
it is reported that the main business income of the top 100 companies in 2019 reached 929.64 billion yuan, a growth rate of 10.7%, exceeding the overall growth rate of the pharmaceutical industry by 2.7 percentage points.
from the top 10 list, Yangzijiang Pharmaceutical Group Co., Ltd., Guangzhou Pharmaceutical Group Co., Ltd., China Pharmaceutical Group Co., Ltd. ranked in the top three, three enterprises, the main business income exceeded 40 billion scale.
and Evergrande Group and Hengrui Pharmaceuticals entered the top 10 for the first time, ranking ninth and 10th, respectively.
, Great Group jumped four places from 2018.
company diversified in the field of superior treatment through cross-border mergers and acquisitions.
that Everest Pharmaceuticals, one of the group's subsidiaries, has made a total of five major investments and acquisitions in 2019.
2019, Yuanda Pharmaceuticals acquired the right to sell new compound nasal spray Ryaltris in China for two decades, and in October 2019, Yuanda Pharmaceuticals acquired a 44% stake in OncoSecMedeical Incorated and acquired TAVO, its global start-up gene immunotherapy product, in China and 38th. Commercialization interests in Asian countries; in November 2019, Yuanda Pharmaceuticals signed a cooperation agreement with Griffith University in Australia to obtain a global development and commercial interest in global start-up therapeutic by-flu products; in December 2019, Yuanda Pharmaceuticals signed a three-way agreement with Sirtex Technology Pty Ltd. and the Australian National University to obtain a research and development cooperation and intellectual property license related to the PROJECT; Yuanda Pharmaceuticals and Taiwan Quanfu Biotech Co., Ltd. signed a licensing agreement and share subscription agreement, further enriching the ophthalmology sector in the high-innovation barrier product line.
For five major investments and acquisitions, Yuanda Pharmaceuticals said the aim is to further strengthen the company's existing core therapeutic areas of innovative product reserves, accelerate the company's research and development strength, accelerate the internationalization of the layout, and provide impetus for the company's long-term development.
According to the 2019 annual report data disclosed by Yuanda Pharmaceuticals, Yuanda Pharmaceutical's earnings increased by 10.6% YoY, excluding the impact of exchange rate changes, by about 15.6% YoY, with pharmaceutical preparations and devices up about 24.3% YoY.
Jiangsu Hengrui also jumped four places from 2018.
as the domestic traditional pharmaceutical industry from generic drugs to innovative drugs transformation of the head enterprises, the company focused on independent research and development, innovative products to bring rich revenue returns.
2019, Hengrui Pharmaceuticals invested 3,896 million yuan in research and development, up 45.90 percent year-on-year and accounting for 16.73 percent of revenue.
among them, the cost of research and development investment of 3.896 billion yuan, capitalized research and development investment 0, research and development personnel 3442 people, accounting for 14.09 percent of the total number of companies, research and development investment accounted for 16.73 percent of sales revenue.
With high investment in research and development, by the end of 2019, Hengrui had six innovative drugs on the market, namely, Erexi cloth tablets, apatini tablets, thiopental non-gesting injections, Malay acid pyrithione tablets, injections with carelli pearl monoanti, injections of toluene sulfonate remazoleon.
among them, apatinib is the world's first small molecule antiangiogenic target drug proven safe and effective in advanced stomach cancer, and is also the first oral preparation in gastric cancer target drug; The newly approved solid tumor drug has been approved in China and the United States has carried out 15 clinical trials, Kareli zhu single anti as China has independent intellectual property rights of the immunotherapy innovative drug has been approved for the treatment of advanced hepatocellular carcinoma, its layout of more than 30 clinical trials, a wide range of adaptation coverage.
addition to these innovative drugs, Hengrui other innovative drugs in the number of more than 30, and many are in the second and third phase of clinical.
's 2019 annual report shows that the company achieved operating income of RMB23,289 million, up 33.7% YoY, and net profit of RMB5.328 billion, up 31.05% YoY.
also shows that these two ways have become an important means for China's pharmaceutical enterprises to improve their core competitiveness.